Does botulinum toxin alter laryngeal secretions and mucociliary transport?

Journal of Voice

Volumn 12, Issue 3, 1998, Pages 389-398

  Fisher, Kimberly V ^a   Giddens, Cheryl L ^b   Gray, Steven D ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Laryngeal secretions; Larynx; Spasmodic dysphonia; Voice disorders

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; CHOLINERGIC TRANSMISSION; CLINICAL ARTICLE; DYSAUTONOMIA; DYSPHONIA; FEMALE; HUMAN; LARYNX; LARYNX DISORDER; MALE; MUCOCILIARY TRANSPORT; SECRETION; THROAT DISEASE; TREATMENT OUTCOME;

EID: 0031693717     PISSN: 08921997     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0892-1997(98)80030-1     Document Type: Article

References (38)

1. Ludlow CL, Baker M, Naunton RF, Hallett M. Intrinsic laryngeal muscle activiation in spasmodic dysphonia. In: Benecke R, Conrad B, Marsden C, eds. Motor disturbances. New York: Academic Press, 1987:199-30.
2. Ludlow C, Naunton R, Sedory S, Schulz G, Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 1988;38:1220-5.
3. Watson B, Schaefer S, Freeman F, Dembowski J, Kondraske G, Roark R. Laryngeal electromyographic activity in adductor and abductor spasmodic dysphonia. J Speech Hear Res 1991;34:473-82.
4. Brin MF, Blitzer A, Stewart C, Fahn S. Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin: review and technical aspects. In: Blitzer A, Brin MF, Sasaki CT, Fahn S, Harris KS, eds. Neurologic disorders of the larynx. New York: Thieme Medical Publishers, Inc., 1992:215-28.
5. Brin MF. Interventional neurology: treatment of neurological conditions with local injections of botulinum toxin. J Arch Neurobiol 1991;54:7-23.
6. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. (Review). N Engl J Med 1991;324:1186-94.
7. Hesse S, Lucke D, Malezic M. Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiat 1994;57:1321-4.
8. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 1981;33:155-88.
9. McMahon HT, Foran P, Dolly JO, Verhage M, Wiegant VM, Nicholls D. Tetanus toxin and Botulinum toxins type A and B inhibit glutamate-aminobutyric Acid, aspartate and metenkephalin release from synaptosomes. J Biol Chem 1992; 267:21338-43.
10. Binz T, Blasi J, Yamasaki S, et al. Proteolysis of SNAP-25 by types E and A Botulinal neurotoxins. J Biol Chem 1994; 269:1617-20.
11. dePaiva A, Ashton AC, Foran P, Schiavo G, Montecucco C, Dolly JO. Botulinum A like type B and tetanus toxins fulfills criteria for being a zinc-dependent protease. J Neurochem 1993;61:2338-41.
12. Poulain B, Mochida S, Weller U, et al. Heterologous combinations of heavy and light chains from Botulinum neurotoxin A and tetanus toxin inhibit neurotransmitter release in aplysia. J Biol Chem 1991;266:9580-5.
13. Rossetto O, Deloye F, Poulain B, Pellizzari R, Schiavo G, Montecucco C. The metallo-proteinase activity of tetanus and botulism neurotoxins. J Physiol 1995;89:43-50.
14. Schiavo G, Rossetto O, Catsicas S, et al. Identification of the nerve terminal targets of Botulinum neurotoxin serotypes A, D, and E. J Biol Chem 1993;268:23784-7.
15. Hughes J, Blumenthal J, Merson M, Lombard G, Jr VD, Gangarosa E. Clinical features of type A and B food-borne botulism. Ann Int Med 1981;95:442-3.
16. Jenzer G, Mumenthaler M, Ludin H, Robert F. Autonomic dysfunction in botulism B: a clinical report. Neurology 1975; 25:150-3.
17. Konig H, Gassman HB, Jenzer B. Ocular involvement in benign botulism b. Am J Opthamol 1975;80:430-2.
18. Vita G, Girlanda P, Puglisi R, Marabello L, Messina C. Cardiovascular-reflex testing and single-fiber electromyography in botulism. Arch Neurol 1987;44:202-6.
19. Ambache N. A further survey of the action of Clostridium botulinum toxin upon different types of autonomic nerve fibre. J Physiol 1951;113:1-17.
20. Bushara KO, Park DM. Botulinum toxin and sweating. J Neurol Neurosurg Psych 1994;57:1437-38.
21. Girlanda P, Vita G, Nicolosi C, Milone S, Messina C. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiat 1992;55:844-5.
22. Mann AC. Localised autonomic failure due to botulinum toxin injection. J Neurol Neurosurg Psychiat 1994;57:1320.
23. Schulze-Bonhage A, Schroder M, Ferbert A. Botulinum toxin in the therapy of gustatory sweating. J Neurol 1996;243: 143-6.
24. Konig W, vonLeden H. The peripheral nervous system of the human larynx. Arch Otolaryngol 1961;73:21/1-34/14.
25. Larson C, Yoshida Y, Sessle B. Higher level motor and sensory organization. In: Titze I, ed. Vocal fold physiology: frontiers in basic science. San Diego: Singular Publishing Group, 1993:227-75.
26. Tanaka Y, Yoshida Y, Hirano M, Hisano S, Daikoku S. Autonomic innervation of feline laryngeal glands: an immunoelectronmicroscopic study. (Japanese). Nippon Jibiinkoka Gakkai Kaiho 1993;96:1311-9.
27. Tanaka Y, Yoshida Y, Hirano M, Morimoto M, Kanaseki T. Distribution of SP - and CGRP-immunoreactivity in the cat's larynx. J Laryngol Otol 1993;107:522-6.
28. Tanaka Y, Yoshida Y, Hirano M. Precise localization of VIP-, NPY-, and TH-immunoreactivities of cat laryngeal glands. Brain Res Bull 1995;36:219-24.
29. Pastor L, Ferran A, Calvo A, Sprekelsen C, Horn R, Marin J. Morphological and histochemical study of human submucosal laryngeal glands. Anat Rec 1994;239:453-67.
30. Yoshida Y, Tanaka Y, Saito T, Shimazaki T, Hirano M. Peripheral nervous system in the larynx. An anatomical study of the motor, sensory and autonomic nerve fibers. (Review). Folia Phoniatr 1992;44:194-219.
31. Wanner A. Possible control of airway hypersecretion. In: Takishima T, Shimura S, eds. Airway secretions. New York: Marcel Dekker Inc, 1994:630-8.
32. Giddens CL. Evidence for the role of the sensory and/or autonomic nervous systems in spasmodic dysphonia and/or Botox treatment. Unpublished manuscript, University of Oklahoma, Health Sciences Center, Oklahoma City, Okla, 1994.
33. Yoshida Y, Shimazaki T, Tanaka Y, Hirano M. Ganglions and ganglionic neurons in the cat's larynx. Acta Otolaryngol (Stockh) 1993;113:415-20.
34. Castells M, Madrid J, Aviles M, Martinez-Menarguez J, Ballesta J. Cytochemical characterization of sulfo- and sialoglycoconjugates of human laryngeal glandular cells. J Histochem Cytochem 1994;42:485-96.
35. Shin T, Wada S, Maeyama T. Substance P immunoreactive nerve fibers of the canine laryngeal mucosa. In: Dirchner JA, Bless DM, eds. Neurolaryngology: recent advances. Boston: College-Hill Press, 1987:65-74.
36. McDonald E, Marino C. Dry mouth: diagnosing and treating its multiple causes. Geriatrics 1991;46:61-3.
37. Dickson E, Shevky R. Studies on the manner in which the toxin of Clostridium botulinum acts upon the body. 1: The effect upon the autonomic nervous system. J Exp Med 1923; 37:711-31.
38. Fisher K, Scherer R, Guo C, Owen A. Longitudinal phonatory characteristics following botulinum toxin injection. J Speech Hear Res 1996;39.